• TLDR Biotech
  • Posts
  • Biotech & Pharma Updates | January 16 - 19, 2025

Biotech & Pharma Updates | January 16 - 19, 2025

Sage Therapeutics sues Biogen to block $442M takeover attempt, Novo Nordisk's high-dose Wegovy Ph3 trial delivers greater weight loss versus standard dose, U.S. government hands Moderna $590 million to develop bird flu vaccines + 18 more stories

Rachael Kay Albers Awkward Marketing GIF

How do you respond to an unsolicited takeover offer? If you’re Sage Therapeutics, you sue. | Gif: rachaelkayalbers on Giphy

All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1600+ biotech and pharma professionals? Let’s chat. 👍

⬇️ The Good News ⬇️

THE GOOD
Approvals & Labels

AstraZeneca's Calquence (BTK inhibitor) nabs FDA approval for first-line treatment of mantle cell lymphoma, combined with bendamustine (alkylating agent) and rituximab (targeting CD20)
Small molecule, lymphoma, cancer - Read more

Amgen snags FDA approval for Lumakras (targeting KRAS G12C) plus Vectibix (targeting EGFR) combination for metastatic colorectal cancer
Small molecule, colorectal cancer - Read more

AstraZeneca, Daiichi Sankyo score FDA approval for Datroway (targeting HER2) in breast cancer
Monoclonal antibody, breast cancer - Read more

Innovent Biologics, ASK Pharm's limertinib (targeting EGFR TKI-sensitizing mutations, T790M) scores Chinese NMPA approval in non-small cell lung cancer
Small molecule, lung cancer - Read more

IMPACT Therapeutics, Huadong Pharmaceutical’s senaparib (PARP inhibitor) lands Chinese NMPA approval in ovarian cancer
Small molecule, ovarian cancer, fallopian tube cancer, primary peritoneal cancer - Read more

Foundation Medicine's FoundationOne CDx test approved as companion diagnostic for Day One Biopharmaceutical's Ojemda (pan-RAF kinase inhibitor) in glioma
Companion diagnostic, glioma, cancer - Read more

THE GOOD
Business Development

U.S. government hands Moderna $590 million to develop bird flu and influenza vaccines
Vaccine, mRNA, bird flu, influenza - Read more

THE GOOD
Clinical Trials

Novo Nordisk's high-dose Wegovy (semaglutide) delivers greater weight loss in obesity patients versus standard dose in Ph3 trial
GLP-1, obesity - Read more

PRESENTED BY 1440 MEDIA

Seeking impartial news? Meet 1440.

Every day, 3.5 million readers turn to 1440 for their factual news. We sift through 100+ sources to bring you a complete summary of politics, global events, business, and culture, all in a brief 5-minute email. Enjoy an impartial news experience.

⬇️ More Good News ⬇️

THE GOOD
Market Reports

Analysts predict Alzheimer's market to grow from $2.4B to $19B by 2033, led by Eisai/Biogen's Leqembi and Lilly's Kisunla.
Alzheimer’s disease - Read more

THE GOOD
Mergers & Acquisitions

WuXi AppTec sells US medical device testing facilities in Atlanta and St. Paul to regulatory consulting firm NAMSA
Medical device, testing, facility sale - Read more

THE GOOD
Partnerships

Henlius Biotech, Deep Potential Technology partner to leverage AI to develop novel cancer meds across modalities
Antibody-drug conjugate, antibody, small molecule, cancer, AI, drug development - Read more [Press release in Mandarin]

Fermion Technology, Simcere Pharmaceutical partner to develop non-opioid pain hopeful FZ002-037 (SSTR4 agonist)
Small molecule, pain management - Read more

Cytiva, Cellular Origins partner to integrate automated platforms for scalable cell therapy manufacturing
Cell therapy, gene therapy, automated manufacturing, robotic manufacturing - Read more

OpenAI, Retro Biosciences partners to develop AI model GPT-4b micro for protein engineering in longevity research
Protein engineering, longevity, AI - Read more

THE GOOD
Research

UMass Amherst researchers develop BacID, a non-toxic bacterial therapy to deliver cancer drugs directly into tumors, with clinical trials expected in 2027
Bacterial therapy, cancer, drug delivery - Read more

THE GOOD
Strategic Plans

Lykos Therapeutics doesn’t give up on potential FDA approval for their MDMA therapy for PTSD, planning independent data review and an additional Ph3 trial
Small molecule, post-traumatic stress disorder, psychedelic - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

season 3 GIF by SpongeBob SquarePants

Gif: spongebob on Giphy

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

⬇️ The Bad News ⬇️

THE BAD
Clinical Trials

Neurizon Therapeutics' IND application for NUZ-001 placed under clinical hold by FDA, awaiting clarification on safety and dosing information
Small molecule, amyotrophic lateral sclerosis - Read more

THE BAD
Layoffs

Notch Therapeutics cuts jobs to save cash, biding time as part of partner/investor search
Cell therapy, cancer, iPSC-derived cell therapy, T cell therapy - Read more

THE BAD
Politics & Policy

Medicare adds Novo Nordisk’s Ozempic and 14 other drugs to price negotiation list, with new prices effective in 2027
Inflation reduction act, drug pricing, drug pricing negotiations - Read more

⬇️ The Ugly News ⬇️

THE UGLY
Lawsuits

Sage Therapeutics sues Biogen to block $442M takeover attempt, citing violation of standstill agreement despite 30% premium offer
Small molecule, Alzheimer’s disease, Parkinson’s disease, major depressive disorder - Read more

DOJ sues Walgreens for allegedly filling millions of illegitimate prescriptions over a decade-long period starting in 2012
Pharmacy, prescription - Read more

You’re all caught up on the latest Pharma & Biotech News!

Voting Rights Projection GIF by Creative Courage

This year’s MLK Jr. day coincides with President-elect Donald Trump’s inauguration. | Gif: creative-courage on Giphy

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here